STOCK TITAN
  1. Home
  2. News
  3. RNA

Avidity Biosciences Inc - RNA STOCK NEWS

Welcome to our dedicated news page for Avidity Biosciences (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avidity Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avidity Biosciences's position in the market.

News
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Rhea-AI Summary
Avidity Biosciences, Inc. (Nasdaq: RNA) announced the presentation of new data from MARINA-OLE™ trial at the 2024 MDA Conference. Dr. John W. Day will join Avidity management for a live webcast event. The company will showcase multiple posters on rare muscle diseases, including AOC 1001 efficacy and safety data. Avidity is focused on RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
conferences
-
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) granted non-qualified stock options and restricted stock units to new non-executive employees under the 2022 Inducement Plan. The options have an exercise price of $10.16 per share, with vesting over four years. The RSUs will vest in four equal installments on the first four anniversaries of the applicable vesting commencement date. The awards are subject to the terms and conditions of the 2022 Inducement Plan and the terms and conditions of a stock option agreement or RSU agreement, as applicable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
none
-
News
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
Rhea-AI Summary
Avidity Biosciences, Inc. (Nasdaq: RNA) plans to initiate the global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024. The company will report data from all three ongoing clinical programs in 2024, including AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H. Avidity also announced the appointment of Eric B. Mosbrooker as Chief Strategy Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
none
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Avidity Biosciences, Inc. (Nasdaq: RNA) granted non-qualified stock options and restricted stock units to new non-executive employees under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $8.40 per share and will vest over four years, while the RSUs will vest in four equal installments on the first four anniversaries of the applicable vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
none
-
News
Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) announces positive AOC 1044 data in healthy volunteers for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping. AOC 1044 delivered up to 50-times greater concentrations of PMO in skeletal muscle following a single dose compared to peptide conjugated PMOs in healthy volunteers. The company plans to provide a first look at AOC 1044 data in people living with DMD44 in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.28%
Tags
clinical trial
-
News
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) partners with Bristol Myers Squibb (BMY) in a global licensing and research collaboration focused on cardiovascular targets. Avidity will receive $100 million upfront with the potential to receive up to $2.2 billion in milestone payments and up to low double-digit royalties. AOCs, Avidity's proprietary RNA therapeutics, will be utilized in the collaboration, expanding the reach of AOCs through the expansion of the existing relationship with Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) granted non-qualified stock options to purchase 27,000 shares of common stock and 13,500 restricted stock units to eight new non-executive employees under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $5.97 per share and will vest over four years, while the RSUs will vest in four equal installments on the first four anniversaries of the applicable vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
none
-
News
Avidity Biosciences to Participate in Upcoming Investor Conference
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) to Participate in 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
conferences
-
News
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) reported positive AOC 1001 data at World Muscle Society Congress, showing consistent improvement in functional endpoints and long-term safety in people with DM1. AOC 1044 received Orphan Designation for DMD in the US and EU. Avidity remains on track to report data from three clinical programs over the next nine months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
earnings
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Avidity Biosciences grants stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
Stock RNA logo
Avidity Biosciences Inc

Nasdaq:RNA

RNA Rankings

#1874 Ranked by Market Cap
#5049 Ranked by Stock Gains
N/A Ranked by Dividends

RNA Stock Data

1.92B
67.97M
6.41%
85.5%
12.52%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About RNA

avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated